Helen Pettersson

Helen Pettersson

PhD in Tumor Immunology

Role in Pharmnovo: Board member since 2020 representing Almi Invest and Almi Invest Syd.

Born: 1973

Education: PhD in Tumour Immunology, MSc in Biology.

Other current appointments: Investment manager of seven of Almi Invest Syd’s portfolio companies and a board member of five companies.

Work Experience: Helen has a PhD in Tumor Immunology and began her career as a translational cancer researcher. She has for several years worked with project management and network platforms for life science stakeholders from academia, industry and healthcare. Before joining Almi Invest, Helen was a Senior project manager at the Danish-Swedish cluster organization Medicon Valley Alliance and before that a Senior project manager at the science park Medicon Village. Today Helen works as a Investment manager at Almi Invest Syd. She focuses on Life Science and is responsible for the entire investment process.

Holdings: 23 000 shares (Almi Invest and Almi Invest Syd)

Member of:

Latest news

View all
July 17, 2024

17.5m EUR blended funding from EIC

PharmNovo is very pleased to announce that we have been awarded a 2.5m EUR grant and an opportunity for up to 15m EUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.

Read more
June 5, 2024

PharmNovo presenting at the Global Forum

On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.

Read more
March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Read more
March 10, 2024

Meet Bengt von Mentzer, founder and Chief scientific advisor

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

Read more